Short Interest in Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Decreases By 34.6%

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totalling 218,800 shares, a decline of 34.6% from the May 31st total of 334,700 shares. Based on an average daily trading volume, of 4,960,000 shares, the days-to-cover ratio is presently 0.0 days.

Biodexa Pharmaceuticals Price Performance

NASDAQ:BDRX traded up $0.02 during trading hours on Friday, hitting $0.90. 89,689 shares of the company’s stock traded hands, compared to its average volume of 317,465. The stock’s fifty day moving average price is $1.06 and its two-hundred day moving average price is $1.46. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 0.06. Biodexa Pharmaceuticals has a twelve month low of $0.67 and a twelve month high of $9.74.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.